All the Drug Class Drugs
CGRP Antagonist, Monoclonal Antibody. Fremanezumab 225 mg. PREFILLED SYR (sol. for SC inj.): 1,3× 1.5ml. Tmt. is intended for pts. with at least 4 migraine days/month when initiat. tmt. with fremanezumab.
Two dosing options are available:
225 mg once mnthly. (mnthly. dosing) or 675 mg every three mnths. (quarterly dosing).
When switching dosing regimens, the first dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiat. tmt. with fremanezumab, concom. migraine prevent. tmt. may be continued if consid. necessary by the prescriber.
The tmt. benefit should be assessed within 3 mnths. after init. of tmt. Any further decision to continue tmt. should be taken on an individ. pt. basis. Evaluation of the need to continue tmt. is recomm. regularly thereafter.
Missed dose: If a fremanezumab inject. is missed on the planned date, dosing should resume as soon as possible on the indicated dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicat. for prophylaxis of migraine in adult. who have at least 4 migraine days per month.
C/I: Hypersens.
CGRP Antagonist. Atogepant 10 mg, 30 mg, 60 mg. TAB. 4/30 X10/30/60 mg. 10 mg, 30 mg, or 60 mg dly.
Prevent. of episodic migraine in adlts.
C/I:Hypersens.
